Newsfeeds - Spark Newswire

1 minute read

BeyondSpring Stock Is Up More than 300%: What You Need To Know?

Today, 10:39 PM

BeyondSpring Inc (NASDAQ: BYSI) is trading over 300% up during premarket in reaction to topline data from DUBLIN-3 Phase 3 trial evaluating plinabulin in combination with docetaxel.

BYSI

2 minute read

12 Health Care Stocks Moving In Wednesday’s Pre-Market Session

By Benzinga Insights

Today, 10:39 PM

ALDX

4 minute read

BeyondSpring Shares Up 350% Following Results From Its DUBLIN-3 Trial Of Plinabulin In Combo With Docetaxel For Non-Small Cell Lung Cancer Showed Study Met Primary Endpoint

By Benzinga Newsdesk

Today, 10:39 PM

Study met primary endpoint showing statistically significant improvement in overall survival (OS) for the combination vs. docetaxel. Study met key secondary endpoints showing statistically significant improvement for

BYSI

6 minute read

The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs

By Shanthi Rexaline

Today, 10:39 PM

Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.

ABUS

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 10:39 PM

Gainers

ARAY

1 minute read

BeyondSpring Files Prospectus Related To Offer, Sale, From Time To Time Of Up To 10M Ordinary Shares

By Michael Horton

Today, 10:39 PM

-SEC Filing

BYSI

6 minute read

14 Biotech Stocks To Watch Over The Next 6 Months

By Shanthi Rexaline

Today, 10:39 PM

Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.

AERI

1 minute read

Earnings Scheduled For June 16, 2021

By Benzinga Insights

Today, 10:39 PM

Companies Reporting Before The Bell • BeyondSpring (NASDAQ:BYSI) is projected to report earnings for its first quarter.

BYSI

3 minute read

FDA
News

BeyondSpring Reports First Patient Dosed In Triple-Combo Study With Plinabulin, PD-1/PD-L1 Inhibitor, Radiotherapy For Reversal of Resistance to PD-1/PD-L1 Inhibitors in Patients with Advanced Solid Tumors

By Benzinga Newsdesk

Today, 10:39 PM

Resistance to immunotherapy is a severe unmet medical need that plinabulin aims to address in combination with checkpoint inhibitors and radiotherapy First patient who failed Keytruda and chemotherapy has been dosed

BYSI

1 minute read

BeyondSpring’s Plinabulin US Application for Chemo-Induced Neutropenia Under Review

By Vandana Singh

Today, 10:39 PM

The FDA has accepted for review BeyondSpring Inc’s (NASDAQ:BYSI) marketing application seeking approval for the use of plinabulin in combination with…

BYSI